Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5099607 | 0.86 | GSK3B (0.56) | GSK3B | |
| SCHEMBL5104869 | 0.86 | GSK3B (0.60) | GSK3B | |
| SCHEMBL5096235 | 0.85 | GSK3B (0.61) | GSK3B | |
| SCHEMBL2401443 | 0.81 | GSK3B (0.74) | GSK3B | |
| SCHEMBL5096040 | 0.81 | GSK3B (0.67) | GSK3B | |
| SCHEMBL2405106 | 0.81 | GSK3B (0.72) | GSK3B | |
| SCHEMBL2403945 | 0.80 | GSK3B (1.00) | GSK3B | |
| SCHEMBL2403556 | 0.79 | GSK3B (0.70) | GSK3B | |
| SCHEMBL5104924 | 0.78 | GSK3B (0.78) | GSK3B | |
| SCHEMBL5098264 | 0.77 | GSK3B (0.74) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4778657-B2 | — | — | 2011-09-21 | — | — | JP | claimed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | claimed |
| EP-1276738-B8 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-20 | — | — | EP | claimed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | claimed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | claimed |
| EP-1276738-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | Sanofi-Aventis (FR) | 2003-01-22 | — | — | EP | claimed |
| WO-2001070729-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | claimed |
| EP-1276738-B8 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI AVENTIS (FR) | 2008-02-20 | — | — | EP | disclosed |
| EP-1276738-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | Sanofi-Aventis (FR) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001070729-A1 | 2-AMINO-3-(ALKYL)-PYRIMIDONE DERIVATIVES AS GSK3.BETA. INHIBITORS | SANOFI-SYNTHELABO (FR) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | GSK3A, GSK3B, PSEN2 | GSK3B 2/4885GPR18 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.